GO:0015355 secondary active monocarboxylate transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015355 describes the carrier-mediated movement of monocarboxylates (compounds with a single carboxyl group) across membranes by uniport, symport or antiport.
• The SLC16A family (MCT1-MCT14) encodes the majority of secondary active monocarboxylate transporters, with MCT1 (SLC16A1) and MCT4 (SLC16A3) being the most extensively characterized.
• Monocarboxylate transport is proton-coupled and facilitates lactate, pyruvate, and ketone body flux, which is critical for cellular metabolism and pH regulation.
• Charged residues in transmembrane helices and ancillary proteins such as basigin (CD147) determine plasma membrane expression and catalytic activity of MCT1.
• Dysregulated monocarboxylate transport is implicated in cancer (e.g., MCT4 in glioblastoma), metabolic disorders, and CNS pathologies.
• CRISPR knockout, point mutation, and knock-in models are essential for dissecting the specific contributions of individual MCT isoforms to substrate recognition and transport.
Description
Secondary active monocarboxylate transmembrane transporter activity (GO:0015355) is a molecular function that enables the movement of monocarboxylates—any compound containing a single carboxyl group (COOH or COO−)—across biological membranes via a carrier-mediated mechanism. This activity is fundamental to cellular metabolism, as it governs the flux of key metabolites such as lactate, pyruvate, and ketone bodies, which are central to energy production and pH homeostasis. The transport process is termed 'secondary active' because it does not directly hydrolyze ATP; instead, it couples monocarboxylate movement to the electrochemical gradient of a driving ion, typically protons (H+). Researchers study GO:0015355 to understand how cells adapt to metabolic stress, how tumors reprogram their metabolism (the Warburg effect), and how the brain maintains energy supply and neurotransmitter balance. The SLC16A gene family, also known as monocarboxylate transporters (MCTs), represents the principal molecular machinery for this activity in humans. Defects in these transporters are linked to a range of diseases, including cancer, diabetes, and neurological disorders. This article provides a comprehensive overview of GO:0015355, covering its definition, the genes involved, its regulation, disease relevance, and the CRISPR-based methods used to study it. All facts are drawn from authoritative QuickGO data and verified PubMed literature.
secondary active monocarboxylate transmembrane transporter activity At A Glance
| GO ID | GO:0015355 |
|---|---|
| GO term | secondary active monocarboxylate transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | monocarboxylate porter activity |
| Definition | Catalysis of the movement of a monocarboxylate, any compound containing a single carboxyl group (COOH or COO-), by uniport, symport or antiport across a membrane by a carrier-mediated mechanism. |
| Major function | Carrier-mediated transport of monocarboxylates (e.g., lactate, pyruvate, ketone bodies) across membranes, often proton-coupled. |
| Representative genes | SLC16A1 (MCT1), SLC16A3 (MCT4), SLC16A7 (MCT2), SLC16A8 (MCT3), SLC16A14 (MCT14) |
| Cellular location | Plasma membrane, mitochondrial membrane, and other organelle membranes. |
| Associated diseases | Cancer, metabolic disorders, neurological disorders, and monocarboxylate transporter deficiency syndromes. |
What Is GO:0015355?
According to the Gene Ontology, GO:0015355 is defined as 'Catalysis of the movement of a monocarboxylate, any compound containing a single carboxyl group (COOH or COO-), by uniport, symport or antiport across a membrane by a carrier-mediated mechanism.' In simpler terms, it is the protein-mediated transport of small organic acids (like lactate or pyruvate) across cell membranes, often coupled to the movement of another ion such as a proton. This activity is distinct from passive diffusion and from primary active transport that directly uses ATP.
Why Is secondary active monocarboxylate transmembrane transporter activity Important in Cell Biology?
GO:0015355 is essential for understanding how cells manage energy and pH. Monocarboxylates such as lactate and pyruvate are not merely waste products; they are key energy substrates and signaling molecules. Their transport across membranes is vital for metabolic cooperation between cells, such as the lactate shuttle between neurons and glia or between tumor cells and stroma. Moreover, the proton-coupled nature of many MCTs means that their activity directly influences intracellular pH, which in turn affects cell proliferation, migration, and survival. Consequently, this GO term is a focal point for research in cancer metabolism, neurobiology, and metabolic diseases.
• Regulates cellular energy metabolism by facilitating lactate, pyruvate, and ketone body uptake and release.
• Maintains intracellular pH homeostasis through proton-coupled transport.
• Supports the Warburg effect in cancer cells by exporting lactate produced from aerobic glycolysis.
• Enables the astrocyte-neuron lactate shuttle, critical for memory formation and neuronal survival.
• Involved in drug transport and pharmacokinetics, as some MCTs transport pharmacological agents.
• Mutations in MCT genes cause diseases such as monocarboxylate transporter 1 deficiency syndrome.
• Provides targets for cancer therapy, with MCT inhibitors like AR-C155858 showing preclinical efficacy.
• Plays a role in immune cell function and inflammation by regulating lactate flux.
• Contributes to the transport of thyroid hormone derivatives, as shown for TRIAC transporters.
• Essential for normal brain development and function, with MCT14 showing abundant CNS expression.
What Happens During secondary active monocarboxylate transmembrane transporter activity?
Substrate Recognition and Binding
In simple terms: The transporter first grabs the monocarboxylate molecule it needs to move.
The transport cycle begins with the recognition and binding of a monocarboxylate substrate (e.g., L-lactate, pyruvate) to a specific site within the transporter's transmembrane domain. For MCT4, a crucial residue (e.g., in transmembrane helix 1) is involved in L-lactate recognition, as demonstrated by mutagenesis studies. Charged residues in the transmembrane helices of MCT1 and its ancillary protein basigin are also critical for substrate binding and catalytic activity. This binding is stereospecific for certain isoforms, ensuring selectivity.
Proton Coupling and Symport
In simple terms: The transporter moves a proton along with the monocarboxylate, like a package deal.
Most secondary active monocarboxylate transporters function as proton symporters, coupling the downhill movement of H+ to the uphill transport of the monocarboxylate. This coupling is essential for transport activity and is not merely a semantic detail; it directly impacts cell viability by influencing intracellular pH. The stoichiometry is typically 1:1 (H+:monocarboxylate), and the proton gradient is maintained by other transporters or metabolic processes.
Conformational Change and Translocation
In simple terms: The transporter changes shape to shuttle the molecule across the membrane.
Upon binding of both the proton and the monocarboxylate, the transporter undergoes a series of conformational changes that expose the binding site to the opposite side of the membrane. This alternating-access mechanism is characteristic of major facilitator superfamily (MFS) transporters, to which many MCTs belong. The process is reversible, allowing transport in either direction depending on the concentration gradients and membrane potential.
Substrate Release and Reset
In simple terms: The transporter releases its cargo and returns to its original shape to start over.
After translocation, the proton and monocarboxylate are released into the cytoplasm (or extracellular space, depending on direction). The transporter then returns to its initial conformation, ready for another cycle. This step is crucial for maintaining transport efficiency and is influenced by intracellular and extracellular pH. Inhibitors such as AR-C155858 bind to an intracellular site involving transmembrane helices 7-10 of MCT1 and MCT2, blocking this reset step.
Key Genes Involved in GO:0015355 secondary active monocarboxylate transmembrane transporter activity
The following genes encode proteins that exhibit secondary active monocarboxylate transmembrane transporter activity, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC16A1 (MCT1) | Proton-coupled transporter for lactate, pyruvate, and ketone bodies; widely expressed. | Knockout studies show its role in lactate shuttle and cancer metabolism; target of inhibitor AR-C155858. |
| SLC16A3 (MCT4) | High-affinity lactate exporter, particularly in glycolytic tissues. | Crucial for lactate release in cancer; residue involved in L-lactate recognition identified. |
| SLC16A7 (MCT2) | High-affinity pyruvate and lactate transporter, predominantly in neurons. | Involved in neuronal energy metabolism; inhibited by AR-C155858. |
| SLC16A8 (MCT3) | Retinal pigment epithelium-specific lactate transporter. | Role in retinal metabolism and visual cycle. |
| SLC16A14 (MCT14) | Orphan transporter with abundant expression in CNS and kidney. | Histological characterization suggests roles in brain and kidney function. |
| SLC16A2 (MCT8) | Thyroid hormone transporter, also transports monocarboxylates like TRIAC. | Mutations cause Allan-Herndon-Dudley syndrome; TRIAC transport identified. |
| SLC16A10 (MCT10) | Aromatic amino acid transporter with monocarboxylate transport capacity. | Involved in thyroid hormone transport and amino acid metabolism. |
| SLC16A11 | Monocarboxylate transporter associated with type 2 diabetes risk. | Genetic variants linked to insulin resistance. |
| SLC16A13 | Poorly characterized monocarboxylate transporter. | Potential role in metabolic regulation. |
| BSG (Basigin/CD147) | Ancillary protein for MCT1 and MCT4; essential for plasma membrane expression. | Charged residues in basigin determine MCT1 catalytic activity. |
| Embigin (EMB) | Ancillary protein for MCT2 and other MCTs. | Required for proper trafficking and function of MCT2. |
| SLC16A6 (MCT6) | Transports monocarboxylates and drugs. | Potential role in drug disposition. |
| SLC16A5 (MCT5) | Orphan monocarboxylate transporter. | Expression in various tissues; function under investigation. |
| SLC16A4 (MCT5) | Orphan monocarboxylate transporter. | Expression in various tissues; function under investigation. |
| SLC16A9 (MCT9) | Monocarboxylate transporter with carnitine transport activity. | Associated with uric acid levels and gout. |
| SLC16A12 (MCT12) | Creatine transporter with monocarboxylate transport activity. | Mutations cause juvenile cataract. |
| SLC16A11 | Monocarboxylate transporter associated with type 2 diabetes risk. | Genetic variants linked to insulin resistance. |
| SLC16A13 | Poorly characterized monocarboxylate transporter. | Potential role in metabolic regulation. |
How Is secondary active monocarboxylate transmembrane transporter activity Regulated?
The activity of secondary active monocarboxylate transporters is regulated at multiple levels. Transcriptional regulation by hypoxia-inducible factor 1 (HIF-1) increases MCT4 expression under low oxygen, supporting glycolytic metabolism. Post-translational modifications, such as glycosylation of ancillary proteins like basigin, are required for proper plasma membrane trafficking and function. Intracellular pH and substrate availability also modulate transport activity allosterically. Additionally, pharmacological inhibitors such as AR-C155858 can block MCT1 and MCT2 by binding to an intracellular site, providing a tool for regulation studies.
secondary active monocarboxylate transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC16A1 (MCT1) | Cancer, lactic acidosis, monocarboxylate transporter 1 deficiency | Knockout mice, cancer cell lines with MCT1 KO, point mutations in charged residues. |
| SLC16A3 (MCT4) | Glioblastoma, breast cancer, metabolic reprogramming | MCT4 knockout in glioblastoma cells, patient-derived xenografts. |
| SLC16A2 (MCT8) | Allan-Herndon-Dudley syndrome, thyroid hormone resistance | Patient-derived fibroblasts, MCT8 knockout zebrafish, knock-in of patient mutations. |
| SLC16A11 | Type 2 diabetes, insulin resistance | Knockout mice, hepatocyte cell lines, CRISPR point mutation of risk variants. |
| SLC16A14 (MCT14) | CNS and kidney function, orphan transporter | MCT14 knockout mice, histological characterization. |
Cancer Metabolism
Many cancer cells exhibit increased glycolysis and rely on MCT4 to export lactate, maintaining intracellular pH and supporting continued glycolysis. MCT1 is also upregulated in some tumors to import lactate for oxidative metabolism. Inhibitors of MCT1/2, such as AR-C155858, have shown potential in reducing tumor growth in preclinical models. Thus, targeting GO:0015355 activity is a promising anticancer strategy.
Neurological Disorders
In the brain, monocarboxylate transporters are critical for the astrocyte-neuron lactate shuttle, which supports neuronal energy demands during high activity. MCT14 is abundantly expressed in the CNS, suggesting a role in brain metabolism. Dysfunction of MCT8 (SLC16A2) causes Allan-Herndon-Dudley syndrome, a severe neurological disorder due to impaired thyroid hormone transport. Additionally, altered monocarboxylate transport has been implicated in neurodegeneration and epilepsy.
Metabolic Disorders
Genetic variants in SLC16A11 are associated with an increased risk of type 2 diabetes, possibly due to altered monocarboxylate transport in liver and adipose tissue. MCT9 (SLC16A9) transports carnitine and is linked to uric acid levels and gout. These findings highlight the importance of monocarboxylate transport in systemic metabolism.
From secondary active monocarboxylate transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MCT1 mediate lactate import in cancer cells? | SLC16A1 knockout in HeLa or MCF7 cells using CRISPR-Cas9. |
| What is the role of a specific charged residue in MCT4 substrate recognition? | Point mutation (e.g., arginine to alanine) in SLC16A3, expressed in Xenopus oocytes or mammalian cells. |
| Can a disease-associated mutation in SLC16A2 be corrected? | Knock-in of wild-type SLC16A2 in patient iPSCs, followed by neuronal differentiation. |
| Where is MCT14 localized in the brain? | Tagged knock-in of SLC16A14 with GFP in mice, followed by immunohistochemistry. |
| Does overexpression of MCT1 enhance lactate uptake? | Overexpression of SLC16A1 in HEK293 cells, measure lactate transport with radiolabeled substrate. |
| Can CRISPR library screening identify synthetic lethal partners with MCT4? | Genome-wide CRISPR knockout library in MCT4-dependent cancer cells. |
How to Study the secondary active monocarboxylate transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled substrate uptake | Transport rate and kinetics | Characterizing MCT1/4 activity in cell lines. |
| Intracellular pH imaging | Proton flux and pH changes | Assessing proton-coupled transport in live cells. |
| CRISPR knockout screening | Gene essentiality and synthetic lethality | Identifying genes required for growth in glycolytic conditions. |
| Site-directed mutagenesis | Role of specific residues in transport | Mapping substrate binding site of MCT4. |
| Western blotting | Protein expression and membrane localization | Validating knockout or overexpression efficiency. |
| Immunofluorescence | Subcellular localization | Determining plasma membrane vs. intracellular localization. |
| RNA-seq | Transcriptional changes | Assessing compensatory upregulation of other MCTs upon knockout. |
| Proteomics | Protein interaction partners | Identifying ancillary proteins like basigin. |
Transport Assays
Radiolabeled substrate uptake assays (e.g., 14C-lactate) are the gold standard for measuring monocarboxylate transport activity. Cells expressing wild-type or mutant transporters are incubated with labeled substrate, and uptake is quantified by scintillation counting. This method can determine kinetic parameters (Km, Vmax) and inhibitor efficacy.
pH Imaging
Since many MCTs are proton-coupled, changes in intracellular pH can be monitored using fluorescent dyes such as BCECF or pH-sensitive GFP. This approach provides real-time readout of transport activity and its impact on cellular pH homeostasis.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that are essential for cell growth under conditions where monocarboxylate transport is critical, such as in lactate-rich or hypoxic environments. This unbiased approach can reveal novel regulators or synthetic lethal interactions.
Structural and Mutagenesis Studies
Site-directed mutagenesis combined with transport assays helps pinpoint residues critical for substrate binding and catalysis. For example, charged residues in transmembrane helices of MCT1 and basigin have been mutated to assess their role in plasma membrane expression and activity. Homology modeling and cryo-EM can provide structural insights.
How CRISPR Can Be Used to Study GO:0015355 secondary active monocarboxylate transmembrane transporter activity
Knockout
CRISPR-Cas9 knockout of SLC16A genes is used to abolish specific monocarboxylate transport activities. For example, SLC16A1 knockout in cancer cells reduces lactate uptake and alters metabolic flux. Knockout models help determine the contribution of individual isoforms to overall transport and cellular phenotype.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can mimic disease-associated variants or probe structure-function relationships. For instance, mutating a crucial residue in MCT4 (SLC16A3) involved in L-lactate recognition can abolish transport, as shown by Sasaki et al.. Such models are invaluable for understanding substrate specificity.
Knock-in
Knock-in of wild-type or tagged versions of SLC16A genes allows for precise expression control and localization studies. For example, knocking in a GFP tag into SLC16A14 enables visualization of MCT14 in mouse tissues. Knock-in of patient mutations into SLC16A2 can model Allan-Herndon-Dudley syndrome.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of SLC16A genes is used to study gain-of-function effects. Overexpressing MCT1 in cells can enhance lactate uptake and promote oxidative metabolism. This approach is useful for testing whether increased transport activity is sufficient to drive a phenotype.
How EDITGENE Supports secondary active monocarboxylate transmembrane transporter activity Research
Researchers studying secondary active monocarboxylate transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in a specific metabolic or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of SLC16A family members and their regulators.
Contact EDITGENE today to design your custom CRISPR model for secondary active monocarboxylate transmembrane transporter activity research.
Frequently Asked Questions About secondary active monocarboxylate transmembrane transporter activity
What is GO:0015355?
GO:0015355 is the Gene Ontology term for secondary active monocarboxylate transmembrane transporter activity, which describes the carrier-mediated movement of monocarboxylates across membranes by uniport, symport or antiport.
What genes are involved in secondary active monocarboxylate transmembrane transporter activity?
The main genes are SLC16A1 (MCT1), SLC16A3 (MCT4), SLC16A7 (MCT2), SLC16A8 (MCT3), and SLC16A14 (MCT14), among others.
How does monocarboxylate transport work?
Most MCTs couple the transport of a monocarboxylate (e.g., lactate) to the movement of a proton (H+), using the proton gradient as an energy source.
What diseases are associated with monocarboxylate transporters?
They are linked to cancer, neurological disorders like Allan-Herndon-Dudley syndrome, and metabolic conditions such as type 2 diabetes.
What is the role of MCT4 in cancer?
MCT4 exports lactate from glycolytic cancer cells, helping maintain intracellular pH and supporting tumor growth.
How can I study monocarboxylate transport in the lab?
Common methods include radiolabeled substrate uptake assays, pH imaging, and CRISPR knockout models.
What is the difference between MCT1 and MCT4?
MCT1 is widely expressed and can import or export lactate, while MCT4 is primarily an exporter with lower affinity, suited for glycolytic tissues.
Can CRISPR be used to study monocarboxylate transporters?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect the function of specific MCT isoforms.
What are the inhibitors of monocarboxylate transporters?
AR-C155858 is a potent inhibitor of MCT1 and MCT2, binding to an intracellular site involving transmembrane helices 7-10.
Where are monocarboxylate transporters located in the cell?
They are primarily located in the plasma membrane, but some isoforms are also found in mitochondrial or other organelle membranes.
Conclusion
GO:0015355, secondary active monocarboxylate transmembrane transporter activity, is a fundamental molecular function that governs the movement of key metabolic intermediates across cellular membranes. The SLC16A family of transporters, with their diverse isoforms and regulatory mechanisms, plays critical roles in normal physiology and in diseases such as cancer and neurological disorders. Understanding this activity requires a combination of biochemical, genetic, and structural approaches, with CRISPR-based models offering unprecedented precision. EDITGENE's services empower researchers to create tailored cell models to study monocarboxylate transport and its impact on health and disease.
References
- 1. Becker PC et al.. 2024. Identification of Human TRIAC Transmembrane Transporters.. Thyroid 34(7):920-930 PMID: 38801167
- 2. Jaeger E et al.. 2026. Intrinsic Asymmetry in Weak Acid Transmembrane Transporters.. Biomolecules 16(1) PMID: 41594631
- 3. Sasaki S et al.. 2013. Crucial residue involved in L-lactate recognition by human monocarboxylate transporter 4 (hMCT4).. PLoS One 8(7):e67690 PMID: 23935841
- 4. Manoharan C et al.. 2006. The role of charged residues in the transmembrane helices of monocarboxylate transporter 1 and its ancillary protein basigin in determining plasma membrane expression and catalytic activity.. Mol Membr Biol 23(6):486-98 PMID: 17127621
- 5. Bader A et al.. 2020. Transmembrane Facilitation of Lactate/H(+) Instead of Lactic Acid Is Not a Question of Semantics but of Cell Viability.. Membranes (Basel) 10(9) PMID: 32942665
- 6. Roshanbin S et al.. 2016. Histological characterization of orphan transporter MCT14 (SLC16A14) shows abundant expression in mouse CNS and kidney.. BMC Neurosci 17(1):43 PMID: 27364523
- 7. Chaudhary N et al.. 2016. Proteome scale census of major facilitator superfamily transporters in Trichoderma reesei using protein sequence and structure based classification enhanced ranking.. Gene 585(1):166-176 PMID: 27041239
- 8. Ovens MJ et al.. 2010. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10.. Biochem J 425(3):523-30 PMID: 19929853
